Skip to main content Back to Top


Atracurium Injection

Reason for the Shortage

    • West-Ward discontinued atracurium in September 2014.[1]
    • Hospira has atracurium available.[2]
    • Sagent had atracurium on shortage due to product recall.[3] Additional information available at:

Available Products

    • Atracurium Besylate injection, Pfizer, 10 mg/mL, 10 mL multiple dose vial, 10 count, NDC 0040-1105-02
    • Atracurium Besylate injection, Pfizer, 10 mg/mL, 5 mL single dose vial, 10 count, NDC 00409-1109-01
    • Atracurium Besylate injection, Sagent, 10 mg/mL, 10 mL multiple dose vial, 10 count, NDC 25021-0672-10
    • Atracurium Besylate injection, Sagent, 10 mg/mL, 5 mL single dose vial, 10 count, NDC 25021-0659-05

Estimated Resupply Dates

    • All presentations are currently available.

Implications for Patient Care

    • Atracurium is an intermediate-acting neuromuscular blocking agent (NMBA) used to facilitate intubation and relax skeletal muscles as an adjunct to general anesthesia during surgery or mechanical ventilation.[4]


    • Clinicians must use extreme caution when switching between NMBAs.

Alternative Agents & Management

    • Alternative NMBAs vary in onset time and duration of action, particularly based on dose; see the table below. Times to re-dose also differ based on agent and dose. Doxacurium, mivacurium, and tubocurarine have been discontinued.[5,6,7]
    • Non-depolarizing neuromuscular blocking agents may be reversed with neostigmine or edrophonium. Depolarizing NMBAs (ie, succinylcholine) are not reversed by these agents and their toxicity may be worsened by concomitant administration.[5,6,7]
    • Some presentations of alternative agents including pancuronium and vecuronium are in short supply.[8]
    Table 1. Characteristics of NMBAs5,6,7
    NMBAType of NMBAOnset of Action (min)Clinical Duration After Initial Dose (min)
    a Clinical duration of effects may increase or decrease with continued administration of succinylcholine; monitor patients carefully.5,6,7
    AtracuriumNondepolarizing2 to 320 to 35
    CisatracuriumNondepolarizing1.5 to 220 to 35
    PancuroniumNondepolarizing2 to 360 to 100
    RocuroniumNondepolarizing1 to 222 - 67 min (depending on initial bolus dose)
    SuccinylcholineDepolarizing0.5 to 14 to 6a
    VecuroniumNondepolarizing2.5 to 320 to 40


    1. West-Ward, Customer Service (personal communications and website). August 5 and September 5, 2014.
    2. Hospira, (personal communication and website). August 26, October 15, November 15, 2013; February 10, March 20, April 30, May 15, July 18, September 5 and 29, November 4 and 14, December 12, 2014; January 9 and 16, February 3, 23, and 27, March 5, 12, and 27, May 21, June 22, July 17, and September 17, 2015.
    3. Sagent, Customer Service (personal communications). May 21 and 29, July 2 and 12, August 29, September 24, October 22, November 15, December 18, 2012; January 28, February 25, March 29, May 29, July 22, August 19, October 14, November 13, 2013; February 3, March 19, April 24, May 15, July 18, September 5 and 25, October 30, November 13, December 12, 2014; January 8, 15, and 29, February 19 and 26, March 5, 12, and 27, May 21, and June 22, July 16, and September 17, 2015.
    4. Bedford. Atracurium Besylate Injection product label. Bedford, OH; Bedford; October, 2010.
    5. Muscle Relaxants - Adjuncts to Anesthesia. In: Wickersham, R. M., Novak K. K., et al., Eds. (2011). Drug Facts and Comparisons (eFacts). St. Louis, MO, Wolters Kluwer Health, Inc.
    6. Neuromuscular Blocking Agents. In: McEvoy GK, Snow EK, Miller J, eds. AHFS 2011 Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2011:1422-1441.
    7. Baughman VL, Golembiewski J, Gonzales JP, Alvarez, W, eds. Anesthesiology and Critical Care Drug Handbook. 9th ed. Hudson, OH: Lexi-Comp; 2010.
    8. American Society of Health-System Pharmacists. Drug Shortage Resource Center. Accessed on November 2, 2011.


Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 22, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.